<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2254-2884</journal-id>
<journal-title><![CDATA[Enfermería Nefrológica]]></journal-title>
<abbrev-journal-title><![CDATA[Enferm Nefrol]]></abbrev-journal-title>
<issn>2254-2884</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Enfermería Nefrológica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2254-28842021000300262</article-id>
<article-id pub-id-type="doi">10.37551/s2254-28842021023</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reactogenicidad e inmunogenicidad tras la inoculación de vacuna frente a SARS-CoV-2 en personal de diálisis]]></article-title>
<article-title xml:lang="en"><![CDATA[Reactogenicity and immunogenicity after inoculation of SARS-CoV-2 vaccine in dialysis care workers]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerrero-Rodríguez]]></surname>
<given-names><![CDATA[Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernán-Gascueña]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda-Serrano]]></surname>
<given-names><![CDATA[María Blanca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arenas-Jiménez]]></surname>
<given-names><![CDATA[Lola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira-Feijoo]]></surname>
<given-names><![CDATA[Concepción]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sanjuan-Miguelsanz]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Renal Íñigo Álvarez de Toledo Centro Los Llanos 2 ]]></institution>
<addr-line><![CDATA[Getafe Madrid]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Renal Íñigo Álvarez de Toledo  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Renal Íñigo Álvarez de Toledo Centro Orense ]]></institution>
<addr-line><![CDATA[Orense ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Fundación Renal Íñigo Álvarez de Toledo Centro Los Olmos ]]></institution>
<addr-line><![CDATA[Segovia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>262</fpage>
<lpage>270</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2254-28842021000300262&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2254-28842021000300262&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2254-28842021000300262&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Ser personal sanitario en activo supone un factor de riesgo elevado para contraer la infección por SARS-CoV-2. La realización de programas de vacunación es la mejor herramienta disponible para enfrentar este problema. En España, los profesionales sanitarios han sido vacunados de manera prioritaria.  Objetivo:  Evaluar, a través del recuento de anticuerpos en sangre, la inmunogenicidad de las vacunas frente a SARS-CoV-2 en personal de diálisis y los factores relacionados con ella.  Material y Método:  Estudio observacional descriptivo de corte trasversal, multicéntrico. Se realizó una determinación serológica del recuento de anticuerpos totales anti-proteína "S" en las 12 semanas posteriores a la vacunación. La recogida de datos se realizó a través de un cuestionario ad-hoc, online, anónimo y voluntario.  Resultados:  167 participantes, todos vacunados con vacunas ARN. EL 15% había pasado previamente la infección. El 96,4% han desarrollado anticuerpos (media de 15.776±13.640 AU/ml); aquellos profesionales que han pasado previamente la infección tienen un número promedio de anticuerpos significativamente mayor que los que no (23.532 vs 14.381 AU/ml) (p=0,05). La presencia de síntomas como cansancio, cefalea, fiebre y mialgias se asocia, también, a una reactividad significativamente mayor (p=0,004). No existe relación significativa entre la reactividad y sexo, edad, índice de masa corporal (IMC) o lugar de trabajo.  Conclusiones: La inmunogenicidad provocada por las vacunas ARN administradas a personal de diálisis ha sido casi total. Padecer efectos adversos post vacunación, como cansancio, cefaleas, fiebre, náuseas y dolores, y haber pasado previamente la infección se asocia con mayor reactividad, manifestada con el desarrollo de mayor número de anticuerpos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Being an active healthcare worker is a high-risk factor for contracting the SARS-CoV-2 infection. The implementation of vaccination programs is the best option available to solve this problem. In Spain, healthcare professionals have been vaccinated as a matter of priority.  Objective:  To assess, through blood antibody counts, the immunogenicity of SARS-CoV2 vaccines in dialysis personnel and related factors.  Material and Method:  Observational, cross-sectional and multicentric descriptive study.  Results: 167 participants, all vaccinated with RNA vaccines. 15% have previously passed the infection. 96.4% have developed antibodies (mean of 15,776 +/-13,640). Those professionals who have previously passed the infection have a significantly higher average number of antibodies than those who have not (23,532 vs 14,381) (p=0.05). The presence of symptoms such as fatigue, headache, fever, and myalgia is also related with a significantly greater reactivity (p=0.004). There is no significant relationship between reactivity and sex, age, BMI, or workplace.  Conclusions:  Immunogenicity caused by RNA vaccines administered to dialysis personnel has been almost complete. Suffering post-vaccination adverse effects such as fatigue, headaches, fever, nausea, pain, and having previously passed the infection is related to a greater reactivity, manifested by the development of an increased number of antibodies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[coronavirus]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[vacuna]]></kwd>
<kwd lng="es"><![CDATA[personal sanitario]]></kwd>
<kwd lng="es"><![CDATA[hemodiálisis]]></kwd>
<kwd lng="en"><![CDATA[coronavirus]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[vaccine]]></kwd>
<kwd lng="en"><![CDATA[health care worker]]></kwd>
<kwd lng="en"><![CDATA[hemodialysis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Gennaro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Murri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Segala]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Cerruti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Abdulle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saracino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Results from a National Survey in Italy]]></article-title>
<source><![CDATA[Viruses]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Grupo de Trabajo Técnico de Vacunación COVID-19, de la ponencia de programa y registro de vacunaciones</collab>
<source><![CDATA[Estrategia de vacunación frente a COVID-19 en España. Actualización 5]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy]]></article-title>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Álvarez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[de Sequera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posicionamiento de la Sociedad Española de Nefrología ante la vacunación frente al SARS-CoV-2]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<source><![CDATA[Estrategia de vacunación frente a COVID-19 en España]]></source>
<year>2021</year>
<publisher-name><![CDATA[Consejo Interterritorial. Sistema Nacional de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Greiner]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Maxwell-Schmidt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[La­mothe]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Vesonder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for Frontline Health Care Staff Safety for COVID-19]]></article-title>
<source><![CDATA[Journal of Primary Care and Community Health]]></source>
<year>2020</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Regev-Yochay]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Afek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kreiss]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Leshem]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>6</volume>
<numero>397</numero>
<issue>397</issue>
<page-range>875-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Foulkes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saei]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oguti]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Charlett]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccibe coverge in healthcare workers in England]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soiza]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Scicluna]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of COVID-19 vaccines in older people]]></article-title>
<source><![CDATA[Age and Ageing]]></source>
<year>2021</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>279-83</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klimek]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bergmann]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Brehler]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pfützner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zuberbier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGA­KI, GPA and ÖGAI]]></article-title>
<source><![CDATA[Allergo J Int]]></source>
<year>2021</year>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Abbott</collab>
<source><![CDATA[AdviseDx SARS-CoV-2 IgG II]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[Actualización nº 405. Enfermedad por el coronavirus (COVID-19)]]></source>
<year>2021</year>
<publisher-name><![CDATA[Ministero de Sanidad. Gobierno de España]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mallapaty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccines are curbing COVID Data from Israel show drop in infections]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>590</volume>
<numero>7845</numero>
<issue>7845</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<source><![CDATA[Estudio ENE-COVID: Cuarta Ronda. Estudio nacional de sero-epidemiología de la infección por SARS-CoV-2 en España]]></source>
<year>2020</year>
<publisher-name><![CDATA[Instituto de Salud Carlos III, Ministerio de sanidad y Ministerio de ciencia e innovación]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aschwanden]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Five reasons why herd immunity for COVID is probably impossible]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>591</volume>
<numero>7851</numero>
<issue>7851</issue>
<page-range>520-2</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jahn M]]></surname>
<given-names><![CDATA[Korth J]]></given-names>
</name>
<name>
<surname><![CDATA[Dorsch O]]></surname>
<given-names><![CDATA[Anastasiou OE]]></given-names>
</name>
<name>
<surname><![CDATA[Roge-Hädicke]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Humoral response to SARS-CoV-2-vaccination with BNT162b2 (pfizer-biontech) in patients on hemodialysis]]></article-title>
<source><![CDATA[Vaccines]]></source>
<year>2021</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<source><![CDATA[Monográfico vacunación COVID-19. La realidad tras los ensayos clínicos]]></source>
<year>2021</year>
<publisher-name><![CDATA[Comité Científico del ICOMEM sobre la COVID-19]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<source><![CDATA[Estrategia de detección precoz, vigilancia y control de COVID-19]]></source>
<year>2021</year>
<publisher-name><![CDATA[Instituto Carlos III. Ministerio de Sanidad. Gobierno de España]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<source><![CDATA[Vacunas COVID-19. Informe de farmacovigilancia Número 5]]></source>
<year>2021</year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabal]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Amram]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Beiruti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sussan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zarka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of age gender ethnicity and prior disease status on immunogenicity following]]></article-title>
<source><![CDATA[MedRxiv]]></source>
<year>2021</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
